Editas reports Q2 2026 results, plans Australia CTN filing for EDIT-401
The gene editing company said it is on track to submit a clinical trial application this month and expects a data update in early 2027.
Editas Medicine reported second quarter 2026 financial results and business updates on August 5, 2026. Editas is on track to submit a Clinical Trial Notification (CTN) in Australia this month and continues to progress towards initiating a Phase 1/2 clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH).1
The planned study will evaluate safety, tolerability, and efficacy of a single dose of EDIT-401, using a two-part design where Part 1 is a single ascending dose, open-label trial.1 The company has selected four clinical trial sites across Australia and New Zealand.1 Editas plans to complete enrollment in Part 1, the dose-finding portion of the trial, with topline data available in 2027.1 The company expects to report a data update in the first quarter of 2027.1
On the preclinical side, a single dose of EDIT-401 achieved roughly 90 percent or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates, with the LDL-C reduction remaining durable through about six months and no adverse clinical observations at a 1.5 mg/kg dose.1
Financially, cash and cash equivalents were $211.6 million as of June 30, 2026, compared to $146.6 million at the end of 2025.1 The company expects this cash to fund operations into the second half of 2028.1 Net loss attributable to common stockholders was $18.2 million, or $0.15 per share, for the quarter, compared to $53.2 million, or $0.63 per share, a year earlier.1
In corporate updates, Editas completed a public stock offering in May with gross proceeds of $125.0 million before expenses.1 The company also appointed Patrick T. Ellinor, M.D., Ph.D. to its board of directors.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.